Bimatoprost

Bimatoprost
(IUPAC) ime
	7-[3,5-dihidroksi-2- (3-hidroksi-5-fenil-pent-1-enil)- ciklopentil]-N-etil-hept-5-enamid
Klinički podaci
Robne marke	Lumigan
AHFS/Drugs.com	Monografija
MedlinePlus	a602030
Identifikatori
CAS broj	155206-00-1
ATC kod	S01EE03
PubChem	5311027
DrugBank	DB00905
ChemSpider	4470565
UNII	QXS94885MZ
ChEBI	CHEBI:51230
ChEMBL	CHEMBL1200963
Hemijski podaci
Formula	C25H37NO4
Mol. masa	415,566 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1 ; Key: AQOKCDNYWBIDND-FTOWTWDKSA-N
Farmakoinformacioni podaci
Licenca	US Daily Med:link
Trudnoća	C(US)
Pravni status	℞-only (SAD)
Način primene	Topikalni (kapi za oči)

Bimatoprost (Lumigan) je analog prostaglandina. On je prolek koji se koristi topikalni (u obliku kapi za oči) za kontrolu progresa glaukoma i okularne hipertenzije. On redukuje intraokularni pristisak (IOP) putem povećanja odliva fluida iz očiju.^[5] Poznato je da se koristi za produžavanje trepavica.^[6] FDA je odobrila ovaj način primene decembra 2008. Kozmetička formulacija bimatoprosta je u prodaji pod imenom Latis.^[7] Tokom perioda od 2008 - 2011, utvrđeno je da bimatoprost ima sposobnost redukovanja masnog tkiva.^[8]^[9]^[10]

Reference[uredi - уреди | uredi izvor]

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. PMID 20331846. doi:10.1186/1758-2946-2-3. edit
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. PMID 21948594. doi:10.1093/nar/gkr777. edit
↑ "Bimatoprost Ophthalmic". MedlinePlus. 1. 1. 2003.. Arhivirano iz originala 05. 10. 2007.. http://web.archive.org/web/20071005013222/http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a602030.html. Pristupljeno 19. 11. 2007..
↑ Rundle, Rhonda L. (19. 11. 2007.). "Drug That Lengthens Eyelashes Sets Off Flutter". The Wall Street Journal. Pristupljeno 19. 11. 2007..
↑ "Allergan gets FDA approval for eyelash treatment". BusinessWeek. Associated Press. 26. 12. 2008. Pristupljeno 26. 12. 2008..
↑ Park J, Cho HK, Moon JI (2011). "Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost.". Japanese Ophthalmological Society 55 (1): 22–27. PMID 21331688. doi:10.1007/s10384-010-0904-z.
↑ Jayaprakasam A, Ghazi-Nouri S. (2010). "Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues.". Orbit 29 (6): 357–359. PMID 21158579. doi:10.3109/01676830.2010.527028.
↑ Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. (2008). "Periorbital changes associated with topical bimatoprost.". Ophthalmology Plastic and Reconstructive Surgery 24 (4): 302–307. PMID 18645437. doi:10.1097/IOP.0b013e31817d81df.

Literatura[uredi - уреди | uredi izvor]

Chen M, Cheng C, Chen Y, Chou C, Hsu W (2006). "Effects of bimatoprost 0.03% on ocular hemodynamics in normal tension glaucoma.". J Ocul Pharmacol Ther 22 (3): 188–93. PMID 16808680. doi:10.1089/jop.2006.22.188.
Kruse P, Rieck P, Sherif Z, Liekfeld A (2006). "Cystoid macular edema in a pseudophakic patient after several glaucoma procedures. Is local therapy with bimatoprost the reason?". Klinische Monatsblätter für Augenheilkunde 223 (6): 534–7. PMID 16804825. doi:10.1055/s-2005-858992.
Steinhäuser S (2006). "Decreased high-density lipoprotein serum levels associated with topical bimatoprost therapy.". Optometry 77 (4): 177–9. PMID 16567279. doi:10.1016/j.optm.2006.02.001.
Park J, Cho HK, Moon JI (2011). "Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost.". Japanese Ophthalmological Society 55 (1): 22–27. PMID 21331688. doi:10.1007/s10384-010-0904-z.
Jayaprakasam A, Ghazi-Nouri S. (2010). "Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues.". Orbit 29 (6): 357–359. PMID 21158579. doi:10.3109/01676830.2010.527028.
Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. (2008). "Periorbital changes associated with topical bimatoprost.". Ophthalmology Plastic and Reconstructive Surgery 24 (4): 302–307. PMID 18645437. doi:10.1097/IOP.0b013e31817d81df.

Spoljašnje veze[uredi - уреди | uredi izvor]

	Portal Medicina
	Portal Hemija

Medical News Today: FDA Seizes $2 Million Of Cosmetic Eye Product Which Contains Drug Ingredient And Makes Unapproved Drug Claims. Christian Nordqvist. 18 November 2007
Wired Science: FDA Seizes Cosmetic That Can Blind. Brandon Keim. November 19, 2007

Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini).

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. PMID 20331846. doi:10.1186/1758-2946-2-3. edit

[4] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. PMID 21948594. doi:10.1093/nar/gkr777. edit

[MedlinePlus-5] "Bimatoprost Ophthalmic". MedlinePlus. 1. 1. 2003.. Arhivirano iz originala 05. 10. 2007.. http://web.archive.org/web/20071005013222/http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a602030.html. Pristupljeno 19. 11. 2007..

[WSJ-19-11-2007-6] Rundle, Rhonda L. (19. 11. 2007.). "Drug That Lengthens Eyelashes Sets Off Flutter". The Wall Street Journal. Pristupljeno 19. 11. 2007..

[7] "Allergan gets FDA approval for eyelash treatment". BusinessWeek. Associated Press. 26. 12. 2008. Pristupljeno 26. 12. 2008..

[JapaneseOphSociety-8] Park J, Cho HK, Moon JI (2011). "Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost.". Japanese Ophthalmological Society 55 (1): 22–27. PMID 21331688. doi:10.1007/s10384-010-0904-z.

[Orbit-9] Jayaprakasam A, Ghazi-Nouri S. (2010). "Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues.". Orbit 29 (6): 357–359. PMID 21158579. doi:10.3109/01676830.2010.527028.

[OphthPlasReconSurg-10] Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. (2008). "Periorbital changes associated with topical bimatoprost.". Ophthalmology Plastic and Reconstructive Surgery 24 (4): 302–307. PMID 18645437. doi:10.1097/IOP.0b013e31817d81df.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

Bimatoprost

Reference[uredi - уреди | uredi izvor]

Literatura[uredi - уреди | uredi izvor]

Spoljašnje veze[uredi - уреди | uredi izvor]

Navigacijski meni

Traži-Тражи